Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:approvalYear |
2022-02-28
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurologic toxicities |
| gptkbp:brand |
gptkb:Carvykti
|
| gptkbp:developer |
gptkb:Janssen_Biotech
gptkb:Legend_Biotech |
| https://www.w3.org/2000/01/rdf-schema#label |
ciltacabtagene autoleucel
|
| gptkbp:indication |
multiple myeloma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells express a chimeric antigen receptor targeting BCMA
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:type |
autologous cell therapy
|
| gptkbp:UNII |
Q2V4Z1FJ1F
|
| gptkbp:usedFor |
relapsed or refractory multiple myeloma
|
| gptkbp:bfsParent |
gptkb:Carvykti
gptkb:TNFRSF17 |
| gptkbp:bfsLayer |
7
|